BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

The trial had 24 patients, exceeding the original target of 20, and included a 4-week baseline. ・In the Absence cohort, patients experienced a median 73.1% reduction in seizures. ・The DEE cohort saw a ...

Date and Time: January 6, 2026, 8AM ET Webcast: ...

Investing.com -- Bright Minds Biosciences (NASDAQ:DRUG) stock rose 5% after the clinical-stage biotechnology company announced positive topline results from its Phase 2 BREAKTHROUGH trial for BMB-101 ...

Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

Bright Minds Biosciences (DRUG) added ~10% in the premarket on Tuesday after the company said that its lead asset, BMB-101, ...

Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...

Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...

Since 1983, eight new AEDs have been introduced (see Table 2 below). Sadly, a recent VA study of more than 21,000 subjects aged 65 years and older revealed that 80% were being treated with ...

New contributions to the field of epilepsy have opened a window into the cellular events that occur in the brain during absence seizures. At first, the teacher described her six-year-old student as ...

Like many teenagers, Danielle Holton's first car was a ticket to freedom. At age 17, she bought a used Hyundai wagon from her mom, paying for it with money from her job as a certified nursing ...